🇺🇸 Travoprost and Timolol in United States

22 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 22

Most-reported reactions

1. Uveitis — 4 reports (18.18%)
2. Intraocular Pressure Increased — 3 reports (13.64%)
3. Optic Nerve Cupping — 3 reports (13.64%)
4. Chorioretinal Disorder — 2 reports (9.09%)
5. Condition Aggravated — 2 reports (9.09%)
6. Drug Ineffective — 2 reports (9.09%)
7. Intraocular Pressure Fluctuation — 2 reports (9.09%)
8. Visual Acuity Reduced — 2 reports (9.09%)
9. Anaemia — 1 report (4.55%)
10. Arthralgia — 1 report (4.55%)

Source database →

Frequently asked questions

Is Travoprost and Timolol approved in United States?

Travoprost and Timolol does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Travoprost and Timolol in United States?

Afyon Kocatepe University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.